Atea Pharmaceuticals, Inc. (AVIR)
AVIR Stock Price Chart
Explore Atea Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze AVIR price movements and trends.
AVIR Company Profile
Discover essential business fundamentals and corporate details for Atea Pharmaceuticals, Inc. (AVIR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Oct 2020
Employees
56.00
Website
https://ateapharma.comCEO
Jean-Pierre Sommadossi
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR Financial Timeline
Browse a chronological timeline of Atea Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.46.
Earnings released on 7 Aug 2025
EPS came in at -$0.44 surpassing the estimated -$0.46 by +4.35%.
Earnings released on 12 May 2025
EPS came in at -$0.40 surpassing the estimated -$0.56 by +28.57%.
Earnings released on 6 Mar 2025
EPS came in at -$0.40 falling short of the estimated -$0.35 by -14.29%.
Earnings released on 7 Nov 2024
EPS came in at -$0.37 surpassing the estimated -$0.50 by +26.00%.
Earnings released on 7 Aug 2024
EPS came in at -$0.48 surpassing the estimated -$0.77 by +37.66%.
Earnings released on 14 May 2024
EPS came in at -$0.75 falling short of the estimated -$0.61 by -22.95%.
Earnings released on 28 Feb 2024
EPS came in at -$0.47 falling short of the estimated -$0.44 by -6.82%.
Earnings released on 8 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$0.46 by +13.04%.
Earnings released on 8 Aug 2023
EPS came in at -$0.34 surpassing the estimated -$0.47 by +27.66%.
Earnings released on 8 May 2023
EPS came in at -$0.43 surpassing the estimated -$0.51 by +15.69%.
Earnings released on 28 Feb 2023
EPS came in at -$0.41 surpassing the estimated -$0.45 by +8.89%.
Earnings released on 7 Nov 2022
EPS came in at -$0.10 surpassing the estimated -$0.44 by +77.27%.
Earnings released on 8 Aug 2022
EPS came in at -$0.38 surpassing the estimated -$0.52 by +26.92%.
Earnings released on 10 May 2022
EPS came in at -$0.51 surpassing the estimated -$0.58 by +12.07%.
Earnings released on 28 Feb 2022
EPS came in at $1.34 surpassing the estimated $0.17 by +688.24%, while revenue for the quarter reached $192.18M , beating expectations by +124.18%.
Earnings released on 11 Nov 2021
EPS came in at -$0.34 falling short of the estimated -$0.05 by -580.00%, while revenue for the quarter reached $32.81M , missing expectations by -76.85%.
Earnings released on 12 Aug 2021
EPS came in at $0.02 surpassing the estimated $0.01 by +300.00%, while revenue for the quarter reached $60.39M , meeting expectations.
Earnings released on 13 May 2021
EPS came in at $0.34 surpassing the estimated -$0.05 by +780.00%, while revenue for the quarter reached $65.99M , missing expectations by -87.37%.
Earnings released on 30 Mar 2021
EPS came in at $0.96 surpassing the estimated $0.16 by +500.00%, while revenue for the quarter reached $48.63M .
Earnings released on 10 Dec 2020
EPS came in at -$1.74 falling short of the estimated -$1.05 by -65.71%.
Earnings released on 30 Oct 2020
EPS came in at -$0.21 .
AVIR Stock Performance
Access detailed AVIR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.